Human leukocyte antigen (HLA) class I defects in head and neck cancer: Molecular mechanisms and clinical significance

Immunologic Research

Volumn 33, Issue 2, 2005, Pages 113-133

  Ferris, Robert L ^a   Hunt, Jennifer L ^b   Ferrone, Soldano ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antigen processing; Head and neck cancer; Immune escape; T cells

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; CANCER RESISTANCE; CANCER STAGING; CARCINOGENESIS; CELL LINE; DISEASE ASSOCIATION; DISEASE COURSE; FREQUENCY ANALYSIS; GENE FUNCTION; GENE STRUCTURE; GENETIC DISORDER; HEAD AND NECK CANCER; HLA SYSTEM; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; METASTASIS; MOLECULAR MECHANICS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKOCYTES;

EID: 26844579408     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:33:2:113     Document Type: Review

References (82)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
2. Parkin DM, Laara E, Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41:184-197.
3. Vikram B: Adjuvant therapy in head and neck cancer. CA Cancer J Clin 1998; 48:199-209.
4. Thekdi AA, Ferris RL: Diagnostic assessment of laryngeal cancer. Otolaryngol Clin North Am 2002; 35:953-969, v.
5. Vikram B, Strong EW, Shah JP, Spiro R: Failure at distant sites following multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984; 6:730-733.
6. Vikram B, Strong EW, Shah JP, Spiro R: Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984; 6:734-737.
7. Brinkman JA, Fausch SC, Weber JS, Kast WM: Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004; 4:181-198.
8. Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187-207.
9. Dallal RM, Lotze MT: The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000; 12:583-588.
10. Davis MM, Krogsgaard M, Huppa JB, et al: Dynamics of cell surface molecules during T cell recognition. Annu Rev Biochem 2003; 72:717-742.
11. Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-1302.
12. Mayordomo JI, Loftus DJ, Sakamoto H, et al: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357-1365.
13. Whiteside TL: Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002; 12:43-50.
14. Li D, Jiang W, Bishop JS, Ralston R, O'Malley Jr BW: Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Clin Cancer Res 1999; 5:1551-1556.
15. Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW: Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg 2000; 126:345-351.
16. Li D, Zeiders JW, Liu S, et al: Combination nonviral cytokine gene therapy for head and neck cancer. Laryngoscope 2001; 111:815-820.
17. Feinmesser R, Hardy B, Sadov R, Shwartz A, Chretien P, Feinmesser M: Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine. Arch Otolaryngol Head Neck Surg 2003; 129:874-881.
18. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2:293-299.
19. Kaufman HL, Disis ML: Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 2004; 113:664-667.
20. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
21. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676-1680.
22. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A: Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170:797-810.
23. Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF: MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol 1991; 146: 1692-1699.
24. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16:487-494.
25. Sant A, Yewdell J: Antigen processing and recognition. Curr Opin Immunol 2003; 15:66-68.
26. Cresswell P, Lanzavecchia A: Antigen processing and recognition. Curr Opin Immunol 2001; 13:11-12.
27. Evans M, Borysiewicz LK, Evans AS, et al: Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001; 167:5420-5428.
28. Kuckelkorn U, Ferreira EA, Drung I, Liewer U, Kloetzel PM, Theobald M: The effect of the interferon-gamma-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur J Immunol 2002; 32:1368-1375.
29. Goldberg AL, Rock KL: Proteolysis, proteasomes and antigen presentation. Nature 1992; 357:375-379.
30. Hengel H, Koopmann JO, Flohr T, et al: A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997; 6:623-632.
31. Ortmann B, Copeman J, Lehner PJ, et al: A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 1997; 277:1306-1309.
32. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P: Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996; 5:103-114.
33. Snyder HL, Yewdell JW, Bennink JR: Trimming of antigenic peptides in an early secretory compartment. J Exp Med 1994; 180:2389-2394.
34. Serwold T, Gaw S, Shastri N: ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat Immunol 2001; 2:644-651.
35. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL: HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2:113-125.
36. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S: Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003; 62:385-393.
37. Kageshita T, Hirai S, Ono T, Ferrone S: Comparison of the reactivity of frozen and formalin-fixed, paraffin-embedded sections of melanoma lesions with anti-HLA class I mAb. Proc. Twelfth International Histocompatibility Workshop and Conference. Vol. II. (Charron, D., ed.) 1997; EDK:737-739.
38. Campoli M, Cheney R, Rebmann H, et al: HLA antigen changes and cancer: A 2004: Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Conference 2005; IHWG Press:Seattle, WA.
39. Garrido F, Cabrera T, Accolla RS, et al: JLA and Cancer, in HLA and Cancer. Genetic Diversity of HLA: Functional and Medical Implications. Vol. I. 1997, Paris: EDK. 445-452.
40. Houck JR, Sexton FM, Zajdel G: HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1990; 116:1181-1185.
41. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F: Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2:47-54.
42. Mattijssen V, De Mulder PH, Schalkwijk L, Manni JJ, Van't Hof-Grootenboer B, Ruiter DJ: HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer Suppl 1991; 6:95-100.
43. Feenstra M, Rozemuller E, Duran K, et al: Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas. Hum Immunol 1999; 60:697-706.
44. Feenstra M, Veltkamp M, van Kuik J, et al: HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999; 54:235-245.
45. Feenstra M, Verdaasdonk M, van der Zwan AW, de Weger R, Slootweg P, Tilanus M: Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Lab Invest 2000; 80:405-414.
46. Cabrera T, Salinero J, Fernandez MA, Garrido A, Esquivias J, Garrido F: High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol 2000; 61:499-506.
47. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA: Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 2000; 6:2794-2802.
48. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F: Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002; 51:389-396.
49. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F: Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003; 61:211-219.
50. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S: Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003; 9:4043-4051.
51. Weinman EC, Roche PC, Kasperbauer JL, et al: Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer 2003; 97:2203-2211.
52. Francke U, Pellegrino MA: Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. Proc Natl Acad Sci USA 1977; 74:1147-1151.
53. Goodfellow PN, Jones EA, Van Heyningen V, et al: The beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature 1975; 254:267-269.
54. Barnstable CJ, Bodmer WF, Brown G, et al: Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978; 14:9-20.
55. Esteban F, Concha A, Huelin C, et al: Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 1989; 43:436-442.
56. Esteban F, Concha A, Delgado M, et al: Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. Br J Cancer 1990; 62:1047-1051.
57. Murray AK, Vora AR, Parker AJ, Start R, Rees RC: HLA class I alterations in head and neck squamous cell carcinoma. Biochem Soc Trans 1997; 25:266S.
58. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK: An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 1997; 76:836-844.
59. Ha PK, Pai SI, Westra WH, et al: Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res 2002; 8:1203-1209.
60. Garcia-Lora A, Algarra I, Garrido F: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195:346-355.
61. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R: A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248:220-223.
62. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F: Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003; 171:1918-1926.
63. Kageshita T, Wang Z, Calorini L, et al: Selective loss of human leukocyte Class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Research 1993; 53:3349-3354.
64. Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S: Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 1999; 190:205-215.
65. Matsui M, Ikeda M, Akatsuka T: High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. Biochem Biophys Res Commun 2001; 280:1008-1014.
66. Seliger B, Atkins D, Bock M, et al: Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 2003; 9:1721-1727.
67. Romero JM, Jimenez P, Cabrera T, et al: Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005; 113:605-610.
68. Ogretmen B, McCauley MD, Safa AR: Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance. Biochemistry 1998; 37:11679-11691.
69. Nie Y, Yang G, Song Y, et al: DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001; 22:1615-1623.
70. Serrano A, Tanzarella S, Lionello I, et al: Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 2001; 94:243-251.
71. Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M: Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer 2003; 105:430-431; author reply 432-433.
72. Ogino T, Wang X, Ferrone S: Modified flow cytometry and cell-ELIS A methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 2003; 278:33-44.
73. Meissner M, Reichert TE, Kunke M, et al: Defects in the HLA class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11:2552-2560.
74. Kim JH, Ajaz M, Lokshin A, Lee YJ: Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Clin Cancer Res 2003; 9:3134-3141.
75. Bolot G, David MJ, Taki T, et al: Analysis of glycosphingolipids of human head and neck carcinomas with comparison to normal tissue. Biochem Mol Biol Int 1998; 46:125-135.
76. Fish RG: Role of gangliosides in tumour progression: a molecular target for cancer therapy? Med Hypotheses 1996; 46:140-144.
77. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114:560-568.
78. Lathers DM, Young MR: Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 2004; 25:220-228.
79. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C: Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001; 61: 5911-5918.
80. Chang CC, Ferrone S: HLA-G in melanoma: can the current controversies be solved? Semin Cancer Biol 2003; 13:361-369.
81. Ferris RL: Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL J Otorhinolaryngol Relat Spec 2004; 66:332-340.
82. Meidenbauer N, Zippelius A, Pittet MJ, et al: High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004; 64:6319-6326.